DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00811460

CompletedPhase 1

A Study of Taspoglutide in Type 2 Diabetic Patients

A Double-blind, Crossover, Randomized, Placebo-controlled Study to Investigate the Effect of Two Different Doses of Taspoglutide IRF Administered as Continuous Subcutaneous Infusion on First- and Second-phase Insulin Secretion in Type 2 Diabetic Patients

Lead sponsor

Hoffmann-La Roche

Asset

Taspoglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

18

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Incremental area under insulin concentration time curve relative to basal

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00811460
Org study IDBP21844
Secondary ID2008-003582-97

Timeline

Milestones

Study first posted2008-12-19estimated
Last update posted2016-11-02estimated
Study start2008-11 (month precision)
Primary completion2009-08actual (month precision)
Study completion2009-08actual (month precision)

Assets

Investigational agents

Taspoglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•adult patients, 18-65 years of age;
•type 2 diabetes mellitus;
•treated with diet and exercise alone, or in combination with stable metformin for at least 3 months prior to screening.

Exclusion criteria

•type 1 diabetes mellitus;
•type 2 diabetes duration of <3 months;
•treatment with any oral anti-hyperglycemic medication other than metformin monotherapy during last 3 months;
•treatment with insulin for >7 days within 6 months prior to screening.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
2
Safety / tolerability / PK
1

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

Incremental area under insulin concentration time curve relative to basal insulin concentration

Time frame:First 10 minutes after glucose bolus

concentration, improvement

Secondary/protocol endpoint

Incremental area under insulin concentration time curve relative to basal insulin concentration

Time frame:10-120 minutes after glucose bolus

concentration, descriptive

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Adverse events, laboratory parameters

Time frame:Throughout study

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.